WebApr 6, 2024 · CTI BioPharma last announced its earnings data on March 6th, 2024. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The firm had revenue of $21.08 million for the quarter, compared to the consensus estimate of $24.88 million. WebCTI BioPharma is a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for …
CTI BioPharma to Participate in Two Upcoming Investor …
WebMedical Information or Adverse Events. If you are seeking medical information or would like to report an Adverse Event (medication side effect) or Product Quality Complaint, please … WebApr 10, 2024 · The employees received options to purchase an aggregate of 36,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock … floating scope
Discover Underlying Factors Driving Myelofibrosis (MF) CTI Biopharma
WebApr 12, 2024 · SEATTLE, Wash., April 12, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development … WebFeb 3, 2024 · --CTI BioPharma Corp. today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2024 in CTI ... WebMar 9, 2024 · Latest Information Update: 03 Feb 2024. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. floating screed definition